Cargando…
On the Management of Drug Interactions in the Course of Concomitant Treatments for COVID-19 and Antineoplastic Agents
Autores principales: | Silvestris, Nicola, Munafò, Antonio, Brunetti, Oronzo, Burgaletto, Chiara, Scucces, Luisa, Bernardini, Renato |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396692/ https://www.ncbi.nlm.nih.gov/pubmed/32850428 http://dx.doi.org/10.3389/fonc.2020.01340 |
Ejemplares similares
-
Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era
por: Burgaletto, Chiara, et al.
Publicado: (2021) -
COVID Vaccination in Cancer Patients: What Vaccination Priority Strategies Should There Be?
por: Silvestris, Nicola, et al.
Publicado: (2021) -
Editorial: The Effect of the COVID-19 Pandemic on Cancer Patients and Healthcare
por: Silvestris, Nicola, et al.
Publicado: (2022) -
Antineoplastic Agents Targeting Sphingolipid Pathways
por: Kroll, Alexander, et al.
Publicado: (2020) -
COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?
por: Brunetti, Oronzo, et al.
Publicado: (2020)